Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02724228 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
A Phase 2 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT02724228 is a Phase 2 study of Achondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 30 participants, below the 148-participant average among 9 other Achondroplasia trials with a reported enrollment target (80% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT02724228, a Phase 2 study of Achondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.
Conditions Studied
Interventions
- DRUG BMN 111
Study Locations (9)
California
- Children's Hospital & Research Center Oakland - Oakland
- Harbor - UCLA Medical Center - Torrance
Other
- Institut Necker - Paris
- Guys & St. Thomas NHS Foundation Trust Evelina Hospital - London
Illinois
- Ann and Robert H. Lurie Childrens Hospital of Chicago - Chicago
Maryland
- Johns Hopkins McKusick - Institute of Genetic Medicine - Baltimore
Tennessee
- Vanderbilt University - Nashville
Texas
- Baylor College of Medicine - Houston
Victoria
- Murdoch Children's Research Institute - Parkville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-01-26 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02724228
The ClinicalTrials.gov registry entry for NCT02724228 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 148-participant average among 9 other Achondroplasia trials with a reported enrollment target (80% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 1 intervention - of which BMN 111 is the first listed.
NCT02724228 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Other, Illinois.
Frequently Asked Questions
What is clinical trial NCT02724228 about?
NCT02724228 is a clinical study titled "A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)". This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed...
What is the current status of trial NCT02724228?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-01-26. Estimated completion is 2028-02.
What conditions does trial NCT02724228 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT02724228?
The interventions under investigation include: BMN 111 (DRUG).
Who is sponsoring clinical trial NCT02724228?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02724228 being conducted?
This trial has 9 study locations across California, Illinois, Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.